| Name | Title | Contact Details |
|---|
Perimeter Solutions is a global specialty chemicals company based in Clayton, Missouri, established in 1963. The company focuses on two main areas: fire safety solutions and lubricant additives. It is a market leader in both sectors, particularly known for its wildfire retardants, firefighting foams, and industrial fire suppressants. Perimeter Solutions offers a range of products, including water-enhancing gels and preventative fire retardants, catering to government agencies, municipalities, and industrial clients worldwide. In addition to fire safety, Perimeter Solutions specializes in niche engine oil additives, holding a significant market share in this area. These additives improve lubricant performance for both automotive and industrial applications. The company is publicly traded under the ticker PRM and is co-founded by Nick Howley, who also chairs the company. With a strong emphasis on innovation and a robust manufacturing and distribution network, Perimeter Solutions positions itself as a premier provider of chemical solutions in its industries.
SCC was originally founded in 2006, and initially conceived as a direct marketing arm for dealerships. Distinguishing itself by offering premium plans directly to consumers underwritten by A-rated insurers, SCC helps car owners find the right vehicle protection plans within their budget. Our VSC (Vehicle Service Contract) agents walk consumers through the many options available to help navigate the extended auto warranty landscape. Our mission at Secure Car Care is to help you have a better car repair experience by finding the best protection plan for you and your vehicle.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.